Coloplast enters partnership with Danish biotech company  

The Danish medico concern has entered a partnership with Nordic Vaccine Technology to develop a vaccine plaster

The Danish medical device concern Coloplast has entered a partnership with biotech company Nordic Vaccine Technology to develop a vaccine plaster. Coloplast is part of an overall DKK 7.5 million (USD 1.2 million) investment in Nordic Vaccine Technology to further the development of the plaster to clinical trials in 18 months time. Other investors include DTU innovation, the Danish Fund for Industrial Growth, Syddansk Innovation and Biolink Capital.


Nordic Vaccine Technology plasters make it possible to transdermally absorb a vaccine that would otherwise have to be injected. Vaccine plasters are thought to have a great potential because they can easily be distributed by post. This means that in crisis circumstances a whole population could be vaccinated in as little as a week. Nordic Vaccine Technology aims to sell its technology on license and the first plasters are expected to be ready for marketing in five years. The news is reported by financial newspaper Børsen online.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×